Empowered by leading technologies as well as years of experience in this field, Creative Biolabs has successfully launched an innovative anti-drug antibody (ADA) development platform with multiple high-end technologies to discover antibodies against therapeutic antibodies.
Background of ADA
In 1982, the first recombinant human protein insulin got its approvals. Three years later, the first therapeutic monoclonal antibody Muromonab-CD3, OKT3 was approved. Both of them symbolized the start of the new biotherapeutic era. Since then, the development of biotherapeutics (e.g. biologics, biopharmaceuticals, biological products, and biological medicinal products/drugs) has increased. Currently, more than 250 approved biotherapeutics are available for unmet medical needs and there are estimated >500 biotherapeutics at various stages of development. However, one of the major side effects of the large molecule-based biotherapeutics lies at the potential of biotherapeutics to produce unwanted immunogenicity. That means the patient's immune system recognizes the administered biotherapeutic as foreign and produces ADA against the foreign molecule. Since almost all protein-based biotherapeutics have the potential to induce immunogenicity, even humanized and fully human monoclonal antibodies, large efforts have been made to reduce drug immunogenicity, particularly in the therapeutic monoclonal antibody field.
High-end Technologies to Develop ADA
ADA can be used as a positive control or reference standard in immunogenicity assays. Therefore, develop functional antibodies for ADA (anti-idiotypic antibody) is required. Creative Biolabs offers robust technologies to fulfill the demands.
Hybridoma technology has long been the classic approach and milestone for the generation of monoclonal antibodies. As a well-established methodology, hybridoma technology can be used to obtain high-affinity binders against certain antibody drugs. Creative Biolabs has years of experience in antibody discovery by hybridoma. Special adjuvant, high fusion efficiency, and unique high-throughput screening approaches promise the highest success rate of each case.
Phage display emerged as a promising alternative for antibody generation. We are capable of selection binders from native libraries or libraries derived from immunized animal hosts. ADA in different formats (Fab, scFv, VHH) are available upon request. Our library construction service and multiple ready-to-use premade libraries support your project in different timeline.
As a new technology, single B cell sorting offers native VH/VL paired antibodies with the best developability. Based on antigen-specific B lymphocytes cytometry technology, we can analyze and isolate every single cell that can interact with the specific target from the whole B cell repertoire.
Features of our Services
With the help of our well-established technologies and experienced scientists, Creative Biolabs is capable of developing positive control antibodies for neutralizing and non-neutralizing ADA assay. Both neutralizing antibody (NAb) and non-neutralizing antibody / binding antibody (BAb) can be produced in rodents or monkeys according to FDA guidance. We provide very flexible options for each specific case. We are happy to make it accessible to all kinds of research and industrial customers. Besides, we are open to discussions. Please don't hesitate to contact us for more information.
For Research Use Only.
